Somahlution LLC provides medical products focused on ischemia reperfusion injury using patented and proprietary technologies. It offers DuraGraft, one time intraoperative vascular graft treatment that maintains endothelial function and structure. The company was founded by Vithalbhai Dhaduk and C. Satish Chandran in 2010 and is headquartered in Jupiter, FL.

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides near-comprehensive healthcare services to eligible military veterans at VA medical centers and outpatient clinics located throughout the country; several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members at 135 national cemeteries.

Otsuka Pharmaceutical Factory, Inc. manufactures and distributes pharmaceutical and nutritional products. Its products include medical foods, hine E-gel, processlead, engelead, innerpower, oronine h ointment, urepearl plus lotion 10 and urepearl plus cream. The company was founded on September 1, 1921 and is headquartered in Naruto, Japan.

OGF SA is a holding company, which owns and operates funeral homes and cemeteries. It manufactures and sells coffins and coffin linings. The firm also offers burial, crematorium management, monuments and cemetery works, and pre-need insurance contracts. The company was founded in 1998 and is headquartered in Paris, France.

Jichi Medical University (自治医科大学 Jichi ika daigaku) is a private university in Shimotsuke, Tochigi, Japan, established in 1972. In 2008 the Gates Foundation awarded $100,000 to Hiroyuki Matsuoka, a medical researcher at the university, to do research on flying syringes.

NICO Corp. develops and manufactures neuro and spinal medical devices. It offers NICO Myriad, a disposable non-heat generating soft tissue resection device; NIC company offers NICO Myriad, a disposable non-heat generating soft tissue resection device and NICO BrainPath products that provide access for the visualization of abnormalities in the subcortical space of the brain. The company was founded by James R. Baumgardt, Jim Person, Joseph L. Mark, Jeffrey Hanthorn in October 17, 2007 and is headquartered in Indianapolis, IN.

Organ Recovery Systems, Inc. provides and transplantation technologies. Its products include LifePort sterile disposables, cargo carte, kidney perfusion solution, data station, battery cap, power cord, data cable, insulating cover and ice containers. The company was founded by David Kravitz in 1998 and is headquartered in Chicago, IL.

Marizyme is a development-stage company dedicated to the commercialization of therapies that address the urgent need for higher mortality and costs in the acute care space. The company's first product candidates are derived from a broad intellectual property portfolio around a novel system of proteolytic enzymes called ProteomeX (previously referred to as Krillase Technology). Marizyme completed the acquisition of these assets and intends to immediately develop several product candidates that will address unmet medical needs in the acute care setting.

Versitech Ltd. is a Hong Kong Chinese company located in Hong Kong and ultimately controlled by the Government of Hong Kong Special Administrative Region. The firm provides business services.

Avent, Inc., a subsidiary of Avanos Medical, Inc., is an American company that develops and manufactures pharmaceuticals.

Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the first and only water-free technology worldwide for ophthalmology products. With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of patients with eye diseases. Two EyeSol® entities have been developed to distinctly target either predominantly aqueous or evaporative disease and potentially break the vicious circle of DED. Both are currently in phase 3 development: >> NOV03 (100% perfluorohexyloctane) is the first drug developed to treat evaporative DED associated with Meibomian gland dysfunction in a highly effective way. >> CyclASol®, an ophthalmic solution of 0.1% cyclosporine A in EyeSol®, is an anti-inflammatory and immunomodulating drug for the treatment of aqueous deficient DED. Both investigational drugs have shown superior clinical benefit, with an early onset of action and an excellent tolerability profile. NovaTears® water-free eye drops for dry eye disease have CE Marking and are commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm. Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies. More on www.novaliq.com.

Organ Transport Systems is a biomedical company that develops and commercializes portable, hypothermic, oxygenated preservation and transport technology for human organs. The company’s products include LifeCradle HR, a durable perfusion unit and the complimenting single-use, organ chamber, and fluid circuit kit. Organ Transport Systems is based in Dallas, Texas.

Suzhou Yingze Biomedical Technology Co., Ltd., established on 2016-10-20, Business scope includes technology development in biomedicine and medical fields,technical consulting,Technology transfer and related technical services;Chemical raw materials and products,Reagents for biological instruments(Does not contain hazardous chemicals),Instrumentation,Buying and selling of electronic products;R&D of medical devices,Production(According to the scope of production license)and sales(Operate within the scope of the license);Biotechnology Extension Services;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval). (Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:Medical Research and Experimental Development;R&D of industrial enzyme preparations(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) Limited to branch operations:Pharmaceutical commissioned production

Yinfeng Bioengineering Group Co., Ltd., established on 2011-04-19, Business scope includes general items:R&D and application of cell technology;Human stem cell technology development and application;Development of Human Gene Diagnosis and Therapy Technology;Health Consulting Services(Does not include medical services);Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Daily necessities sales;Maternal and baby products sales;Cosmetics Wholesale;Cosmetics Retail.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Class III medical device business;Health food sales;Cosmetic production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Hemarina SA. is a privately held biotechnology company focused on the research, and development of oxygen-carriers for medical applications. Dr. Franck Zal, an expert in the field of invertebrate hemoglobin and oxygen transport, founded Hemarina after having spent more than fourteen years in academic research centers (CNRS, University of California at Santa Barbara USA and University of Antwerpen, Belgium) studying the relationships between the structure and function of invertebrate respiratory pigment (annelid’s extracellular hemoglobin and crustacean hemocyanin). The discoveries arising from his research on extracellular hemoglobin coming from marine invertebrates and their effective oxygen transport system have been patented and published in numerous scientific journals and form the basis of Hemarina’s technologies. Hemarina’s approach to the development of oxygen transport agents is based on the observation of marine worms colonizing extreme environments and the study of their respiratory adaptations. Hemarina’s lead product, HbAm, is designed to deliver oxygen effectively and efficiently to tissues at risk of oxygen deprivation. Hemarina has already a passed panel of strong proof of concepts obtained during preclinical trials.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Zhuhai Besso Cell Science and Technology Co., Ltd., established on 2012-03-15, Business scope includes general items:R&D and application of cell technology;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Sales of Class II Medical Devices;Specialty Chemicals Sales(Free of Hazardous Chemicals);Experimental analysis instrument sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Health Consulting Services(Does not include medical services);Import and export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Production of Class II Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Danwang Medical provides clinical transformation technology services to regenerative medicine for disease diagnosis and treatments. They also provide organoid drug sensitivity testing, organoid disease models, organoid drug development, and organoid chips. Danwang Medical is committed to applying the most recent clinical transformation technology of regenerative medicine to disease diagnosis and treatment, new drug screening, tumor marker development and identification, and other areas in order to provide clinical personalized treatment technology and accurate, efficient, and high-quality organoids Model to new drug research and development enterprises.

Greenblendz, Inc. is a private company headquartered in Auburn Hills, MI. The firm engages in blending, packaging and filling chemicals.